- Advanced search
- Immuno Portal
- Malaria Portal
Synonyms: AN100226 | anti-alpha4 integrin | anti-VLA4 | Tysabri®
natalizumab is an approved drug (FDA (2004), EMA (2006))
Compound class: Antibody
Comment: Natalizumab was the first migration-inhibitory biological drug to be approved for inflammatory diseases.
Targeting cell migration-related molecules in immune conditions (and cancer) is regarded as a significant new focus for the development of novel anti-inflammatory therapeutics .
The design and synthesis of this antibody is described in , but the article is not open access.
View more information in the IUPHAR Pharmacology Education Project: natalizumab
|We have been unable to find affinity data for this antibody from an open access article.|
|Selectivity at catalytic receptors|
|Key to terms and symbols||Click column headers to sort|
|Ligand mentioned in the following text fields|